The full $2M facility is now drawn. Monitor for any future amendments or additional debt raises, as the company has no remaining committed undrawn capacity under this agreement. The 12% cash-pay interest and warrant coverage suggest continued reliance on expensive debt financing.
Price Chart
Executive Summary
Nuo Therapeutics closed the $325,000 Second Funding tranche under its existing Loan Agreement on October 6, 2026, bringing total drawn debt to $2,000,000. An existing lender assigned $100,000 of its commitment to three new unaffiliated lenders and board member Scott M. Pittman, who increased his total loans to $425,000. The company issued secured promissory notes at 12% interest (maturity Dec 31, 2028) and warrants exercisable at $1.50/share, with aggregate warrant coverage unchanged. This is a routine debt drawdown with no material change to economic terms.
Key Financial Metrics
Key Facts
- Second Funding of $325,000 closed on October 6, 2026, completing the full $2,000,000 total funding commitment under the Loan Agreement.
- An existing lender assigned $100,000 of its $150,000 Second Funding commitment to four Assuming Lenders: three new unaffiliated parties and board member Scott M. Pittman.
- Scott M. Pittman assumed $25,000 of the assigned commitment, bringing his total loans to $425,000 ($200,000 initial + $100,000 interim + $125,000 second).
- Second Notes bear 12% annual interest, mature December 31, 2028, with interest payable in warrants.
- Warrants issued to Assuming Lenders: 18,000 immediately exercisable Second Restated Warrants, 1,832 contingent Prepayment Restated Warrants, and up to 11,000 Interest Warrants at maturity.
- Warrant exercise price remains $1.50 per share; aggregate warrant coverage was not increased.
- The Amendment did not alter any material economic terms of the Loan Agreement.
Financial Impact
Company received $325,000 in new debt proceeds on Oct 6, 2026; total drawn debt under the facility is now $2,000,000. No change to interest rate (12%) or maturity (Dec 31, 2028).
Risk Factors
- Full $2M facility is now drawn with no remaining undrawn commitment, limiting financial flexibility.
- 12% interest rate and warrant-based interest payments indicate high cost of capital for a micro-cap company.
- Director Scott M. Pittman's increasing loan exposure ($425,000 total) creates potential related-party concentration risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032242 |
| Document: aurx20261006c_8k.htm | 0001437749-26-032242 |
| Document: 0001437749-26-032242-index-headers.html | 0001437749-26-032242 |
| Document: 0001437749-26-032242-index.html | 0001437749-26-032242 |
| Document: 0001437749-26-032242.txt | 0001437749-26-032242 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.30 | awaiting T+20 | — | $1.30 (−0.00%) |
Aug 17, 2026 10w ago | 8-K | $1.00 $1.25 | ▲ +25.00% | ▲ +26.53% | $1.30 (+30.00%) |
May 14, 2026 23w ago | 8-K | $1.35 $0.9674 | ▼ −28.34% | ▼ −30.46% | $1.30 (−3.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers